ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Contact information
HyunJung Jung
Business Development Manager
Hyunjung.Jung@ImmunAbs.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Revolutionize Brand Engagement: MSquared Puts Interoperability Center Stage in MLB’s Virtual Ballpark!26.9.2024 22:48:00 CEST | Press Release
Solving the Interoperability Challenge MSquared’s demonstration is the first major showcase of how it has solved the technical challenges of metaverse interoperability. The integration of the Metaverse Markup Language (MML) lies at the heart of this success, offering a revolutionary way to define interactive 3D content that can seamlessly run across different virtual spaces and engines. Additionally, M² has developed a secure digital rights management and moderation system that allows IP owners and consumers to have appropriate protections as content moves freely between worlds. “MSquared has systematically overcome the challenges of interoperability - from ownership to standardized visualizations and secure asset storage,” said Rob Whitehead, Chief Product Officer of Improbable. “Our technology safeguards intellectual property and brand integrity across diverse virtual environments, ensuring seamless and secure experiences.” Elevate Your Brand in the Metaverse This milestone event in
Grid Dynamics Expands Global Footprint with JUXT Acquisition, Strengthening Expertise in Banking and Financial Services26.9.2024 22:05:00 CEST | Press Release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announces its acquisition of JUXT, a UK-based provider of software engineering services specializing in data-intensive information systems for banking and other financial institutions, with a particular focus on risk platforms, structured notes, equity derivatives, and financial reporting. With this acquisition, Grid Dynamics adds significant expertise and capabilities to better serve enterprise clients in the financial services industry. Founded in 2013, JUXT is known for delivering complex end-to-end solutions, from design and user experience, to deep functionality and ongoing managed services. Their specializations in mission-critical platforms and products for leading banks and financial institutions make them a strategically important addition to Grid Dynamics, especially as global demand for reliable
BM3EAC Corp. 2024 Semi-Annual Report26.9.2024 20:58:00 CEST | Press Release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2024 to 30 June 2024. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
UCC Holding Ranked 42 nd in ENR’s Top International Contractors26.9.2024 20:32:00 CEST | Press Release
Urbacon Holding, a leader in energy, concessions, and construction, announced its ranking as the 42nd top international contractor for 2024, according to Engineering News-Record (ENR). The company celebrated this achievement during the ConteQ Expo 2024 in Qatar, where it participated as the event's official sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926450701/en/ UCC Holding Ranked 42nd in ENR’s Top International Contractors (Photo: AETOSWire) The event brought together UCC Holding’s Board of Directors and senior management, who emphasized the company’s ongoing efforts to integrate advanced construction technologies into its operations. During the expo, UCC Holding introduced three innovative construction methods: 3D construction printing, concrete modular construction, and steel structure modular construction. These technologies are already being incorporated into UCC’s future projects, including a series of
Sinopec Awarded Best Environmental Protection Case at First Sino-European Corporate ESG Best Practice Conference26.9.2024 19:06:00 CEST | Press Release
The ESG case from China’s Sinopec, titled “Empowering Green Development, Co-Creating a Zero-Carbon Future,” stood out from dozens of entries and was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926903754/en/ An ESG case from China’s Sinopec was awarded the Best Case in the Environmental Protection category at the first Sino-European Corporate ESG Best Practice Conference held in Frankfurt, Germany. (Photo: Business Wire) Walter Döring, Chairman of German World Market Leaders Association, on behalf of the event's organizing committee, announced the results. He stated, “Sinopec has demonstrated exceptional practical value in environmental protection. Through its comprehensive environmental management system and innovative technological means, as well as the use of cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom